Stock Scorecard
Stock Summary for Lantern Pharma Inc (LTRN) - $2.58 as of 2/6/2026 6:21:10 PM EST
Total Score
11 out of 30
Safety Score
16 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for LTRN
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for LTRN
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for LTRN
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for LTRN
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for LTRN (16 out of 100)
| Stock Price Rating (Max of 10) | 3 |
| Historical Stock Price Rating (Max of 10) | 4 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 0 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 4 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for LTRN
Financial Details for LTRN
Company Overview |
|
|---|---|
| Ticker | LTRN |
| Company Name | Lantern Pharma Inc |
| Country | USA |
| Description | Lantern Pharma Inc. (LTRN) is an innovative clinical-stage biotechnology company based in Dallas, Texas, focused on transforming cancer treatment through precision oncology. Leveraging a proprietary technology platform that combines artificial intelligence with genomic data, Lantern significantly enhances drug discovery processes and tailors oncology therapies to the unique genetic profiles of individual tumors. This data-driven approach not only aims to improve therapeutic outcomes but also positions the company as a frontrunner in addressing the complexities of cancer, catering to the diverse needs of patient populations in a rapidly advancing field. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 3/26/2026 |
Stock Price History |
|
| Last Day Price | 2.58 |
| Price 4 Years Ago | 6.04 |
| Last Day Price Updated | 2/6/2026 6:21:10 PM EST |
| Last Day Volume | 118,229 |
| Average Daily Volume | 56,483 |
| 52-Week High | 5.74 |
| 52-Week Low | 2.55 |
| Last Price to 52 Week Low | 1.18% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 23.21 |
| Sector PE | 34.82 |
| 5-Year Average PE | -3.96 |
| Free Cash Flow Ratio | 3.44 |
| Industry Free Cash Flow Ratio | 12.52 |
| Sector Free Cash Flow Ratio | 33.33 |
| Current Ratio Most Recent Quarter | 3.33 |
| Total Cash Per Share | 0.75 |
| Book Value Per Share Most Recent Quarter | 0.87 |
| Price to Book Ratio | 3.63 |
| Industry Price to Book Ratio | 53.70 |
| Sector Price to Book Ratio | 53.77 |
| Price to Sales Ratio Twelve Trailing Months | 0.00 |
| Industry Price to Sales Ratio Twelve Trailing Months | 21.10 |
| Sector Price to Sales Ratio Twelve Trailing Months | 17.66 |
| Analyst Buy Ratings | 2 |
| Analyst Strong Buy Ratings | 0 |
Share Statistics |
|
| Total Shares Outstanding | 11,184,400 |
| Market Capitalization | 28,855,752 |
| Institutional Ownership | 20.13% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -30.20% |
| Reported EPS 12 Trailing Months | -1.75 |
| Reported EPS Past Year | -1.21 |
| Reported EPS Prior Year | -1.93 |
| Net Income Twelve Trailing Months | -18,920,421 |
| Net Income Past Year | -20,781,213 |
| Net Income Prior Year | -15,961,534 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 8,389,486 |
| Total Cash Past Year | 7,511,079 |
| Total Cash Prior Year | 21,937,749 |
| Net Cash Position Most Recent Quarter | 8,389,486 |
| Net Cash Position Past Year | 7,511,079 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 21,187,774 |
| Total Stockholder Equity Prior Year | 40,907,934 |
| Total Stockholder Equity Most Recent Quarter | 9,586,838 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -16,861,459 |
| Free Cash Flow Per Share Twelve Trailing Months | -1.51 |
| Free Cash Flow Past Year | -17,825,800 |
| Free Cash Flow Prior Year | -14,365,282 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | None |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.00 |
| MACD Signal | 0.00 |
| 20-Day Bollinger Lower Band | 2.76 |
| 20-Day Bollinger Middle Band | 3.60 |
| 20-Day Bollinger Upper Band | 4.45 |
| Beta | 1.52 |
| RSI | 39.82 |
| 50-Day SMA | 0.00 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 2/3/2026 10:07:01 PM EST |